GLP-1R/GCGR DUAL-TARGET AGONIST PEPTIDE DERIVATIVES FOR TREATMENT OF VIRAL HEPATITIS-RELATED HEPATIC FIBROSIS

摘要

Provided is use of polypeptide compounds having dual agonistic effects of a glucagon-like peptide-1 receptor (GLP-1R) and a glucagon receptor (GCGR). The compounds have characteristics such as high enzymatic hydrolysis stability and high biological activity without adverse reactions, and can significantly improve hepatic fibrosis caused by hepatitis B virus (HBV) and hepatitis C virus (HCV) and the degree of fibrosis accompanied by liver diseases. The dual-target agonist peptide derivatives can be used for preventing or treating viral hepatitis-related hepatic fibrosis.